Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

TRVN opened at $1.71 on Monday. Trevena has a 1 year low of $1.13 and a 1 year high of $19.23. The firm has a 50 day moving average price of $1.72 and a 200 day moving average price of $3.54. The company has a market cap of $1.48 million, a PE ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million for the quarter. On average, sell-side analysts predict that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.